NanoViricides (NNVC)
Develops host-mimetic antiviral candidates for multiple viral diseases.
Something off on this page? Send us feedback.
Develops host-mimetic polymeric antiviral candidates and manufactures limited clinical supplies while outsourcing much of its research and clinical work. Its lead active ingredient is being developed across several viral indications, with no approved drug or product revenue.
Develops host-mimetic polymeric antiviral candidates designed to bind viruses before cell entry and disrupt them. Its lead active ingredient, NV-387, is being advanced across MPox, measles, smallpox, respiratory infections, and other viral targets; a topical NV-HHV-1 skin cream remains deferred.
Research, analytical work, and limited clinical-supply manufacture are centered in Shelton, Connecticut, while clinical and development work relies on TheraCour, contract research organizations, laboratories, and partners in India and the DRC. The company owns an approximately 18,000-square-foot facility but has no large-scale commercial manufacturing, sales, or marketing organization.
Has no approved drug, customer, or product revenue. Core technology rights, development, and supply are licensed from and dependent on TheraCour, which is also controlled by the founder.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $3.2M · Total debt $0 · Total assets $10.2M · Shareholders' equity $9.2M
- Revenue
- $0
- Operating income
- −$2.0M
- Net income
- −$2.0M
No dividends on record.
| Institutions | 9.35% | 2.37M shares | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Other | 90.65% | 23.03M shares | |
| remainder | |||
25.40M company shares as of Sep 13, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (21.65M in the company's Sep 23, 2026 report, 25.40M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 3.62% | 919,313 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.85% | 216,022 | as of Jun 30, 2026 |
Connective Capital Management, LLCInstitution | 0.73% | 185,217 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.63% | 158,753 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.52% | 131,923 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- SIGA
Established orthopox antiviral and biodefense-stockpile rival.
- Emergent BioSolutions
Animal Rule smallpox treatment with stockpile relevance.
- BioCryst Pharmaceuticals
Peramivir treatment overlaps the influenza arm of respiratory use.
- Pfizer
COVID treatment and RSV prevention constrain respiratory entry.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NanoViricides | $1.57 | +2.29% | $38.9M | — | — | — | — |
| SIGA | $3.14 | −3.83% | $233.8M | — | — | 4.4 | −49.5% |
| Emergent BioSolutions | $6.68 | −1.26% | $348.8M | — | — | 0.5 | +66.3% |
| BioCryst Pharmaceuticals | $8.55 | −2.68% | $2.23B | — | 16.3 | 2.4 | +33.6% |
| Pfizer | $27.92 | −0.04% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 36.9 | 13.1 | 2.4 | +18.1% |